A phase III trial published last year showed that dabrafenib combined with trametinib in patients with metastatic disease was superior to dabrafenib alone, in terms of progression - free survival (22 % vs 12 % at 3 years; hazard ratio [HR], 0.71) and overall survival (44 % vs 32 % at 3 years; HR, 0.75). (cancernetwork.com)
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. (hopkinsmedicine.org)
The MEK inhibitor trametinib and the BRAF inhibitor dabrafenib were approved to treat patients with metastatic or unresectable BRAF - mutated melanoma. (cancernetwork.com)